Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LPAR1 | Q92633 | 6/20 | 0.68 |
| ▸ | GPR132 | Q9UNW8 | 1/20 | 0.41 |
| ▸ | CXCR5 | P32302 | 11/20 | 0.39 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.38 |
| ▸ | SMPD1 | P17405 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1560326 | 0.92 | LPAR1 (0.79) | LPAR1GPR132CXCR5 | |
| SCHEMBL1561711 | 0.92 | LPAR1 (0.70) | LPAR1GPR132CXCR5SIRT2SMPD1 | |
| Fipaxalparant SCHEMBL29382253 | 0.84 | LPAR1 (0.78) | LPAR1GPR132CXCR5SMPD1 | |
| SCHEMBL1560931 | 0.84 | LPAR1 (0.78) | LPAR1GPR132CXCR5 | |
| SCHEMBL1560260 | 0.84 | LPAR1 (0.67) | LPAR1GPR132CXCR5SIRT2SMPD1 | |
| Fipaxalparant SCHEMBL29398637 | 0.84 | LPAR1 (0.78) | LPAR1GPR132CXCR5SMPD1 | |
| Fipaxalparant SCHEMBL1560214 | 0.84 | LPAR1 (0.78) | LPAR1GPR132CXCR5SMPD1 | |
| SCHEMBL1561397 | 0.84 | LPAR1 (0.69) | LPAR1CXCR5SMPD1 | |
| SCHEMBL1560271 | 0.83 | LPAR1 (0.70) | LPAR1GPR132CXCR5SMPD1 | |
| SCHEMBL1561481 | 0.82 | LPAR1 (0.78) | LPAR1GPR132CXCR5SMPD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110152290-A1 | ACYLAMINO-SUBSTITUTED FUSED CYCLOPENTANECARBOXYLIC ACID DERIVATIVES AND THEIR USE AS PHARMACEUTICALS | SANOFI-AVENTIS (FR) | 2011-06-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110152290-A1 | ACYLAMINO-SUBSTITUTED FUSED CYCLOPENTANECARBOXYLIC ACID DERIVATIVES AND THEIR USE AS PHARMACEUTICALS | EDF1, LPAR2, LIPG | LPAR1 6/4885GPR132 539/4885CXCR5 438/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.